BioStock: RhoVac gives guidance on new indications for RV001

While testing its candidate RV001 in prostate cancer patients in a phase IIb trial, Lund-based RhoVac is making plans to out-licensing the project. To set the stage for a possible deal, comprehensive market research has been conducted to provide guidance on the medical need for a cancer relapse vaccine in additional cancer indications. Overall, the company concludes that there is great need for a vaccine that prevents tumour recurrence and highlights two cancer indications as particularly interesting.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/rhovac-gives-guidance-on-new-indications-for-rv001/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se